Vitronectin and Integrin alpha(v)Beta3 in Ovarian Carcinoma
Abstract
Ovarian cancer is the leading gynecological cancer that results in death. Due to the lack of symptom in the early stage of disease, most ovarian cancers are diagnosed in the late stage. Current therapy such as chemotherapy is not very effective for curing ovarian cancer. This proposal aims to develop an adenovirus-based gene therapy for suppression ovarian malignancies. In our studies, we have found that the interaction between vitronectin and alphavBETA3 integrin is essential for ovarian cancer cell survival and invasion. We thus developed potent small interfering RNA targeting vitronectin and BETA3 integrin subunit. We inserted these specific siRNAs to adenovirus vector and test whether Ad-delivered siRNA could inhibit ovarian malignancies. We demonstrate that Ad-delivered siRNA can significantly reduce ovarian cancer cell survival and invasiveness as determined by in vitro assays. Using SCID mouse model, we further show that Ad-delivered siRNA also inhibit in vivo tumor development and prolong animal survival. Our study provide the basis to develop an alternative therapeutic modality for ovarian cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2003
- Accession Number
- ADA420884
Entities
People
- Shuang Huang
Organizations
- Scripps Research